Glenmark Launches Tiogiva, Generic Dry Powder Inhaler, in UK

Glenmark Launches Tiogiva, Generic Dry Powder Inhaler, in UK

296936

Glenmark Launches Tiogiva, Generic Dry Powder Inhaler, in UK

Glenmark Pharmaceuticals has launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva is the bioequivalent generic version of Boehringer Ingelheim’s Spiriva Handihaler, which means the therapy works the same way and is considered as effective and safe as the brand name version.  In 2018, Glenmark Pharmaceuticals Europe, a subsidiary of Glenmark, entered into an exclusive in-licensing agreement to market generic tiotropium bromide…

You must be logged in to read/download the full post.